头孢哌酮舒巴坦联合莫西沙星治疗慢阻肺急性加重期的临床效果及对患者肺功能的影响

Clinical Effect of Cefoperazone Sulbactam Combined with Moxifloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Impact on Pulmonary Function of Patients

目的探讨头孢哌酮舒巴坦联合莫西沙星治疗慢阻肺急性加重期(AECOPD)的临床效果及对患者肺功能的影响。方法72例AECOPD患者随机分为两组,对照组采用头孢哌酮舒巴坦治疗,观察组采用头孢哌酮舒巴坦联合莫西沙星治疗,比较两组的临床疗效、肺功能指标(FEV_(1)、PEF)及不良反应。结果治疗后,观察组的总有效率以及FEV_(1)、PEF水平均高于对照组(P<0.05)。两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论头孢哌酮舒巴坦联合莫西沙星治疗AECOPD的效果显著,可促进患者肺功能恢复,且不良反应少。

Objective To explore the clinical effect of cefoperazone sulbactam combined with moxifloxacin in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and its impact on pulmonary function of patients.Methods 72 patients with AECOPD were randomly divided into two groups.The control group was treated with cefoperazone sulbactam,and the observation group was treated with cefoperazone sulbactam combined with moxifloxacin.The clinical efficacy,pulmonary function indicators(FEV_(1),PEF)and adverse reactions were compared between the two groups.Results After treatment,the total effective rate and the levels of FEV_(1) and PEF in the observation group were higher than those in the control group(P<0.05).No statistical difference was found between the two groups in the incidence of adverse reactions(P>0.05).Conclusions Cefoperazone sulbactam combined with moxifloxacin in the treatment of AECOPD has significant effect,which can promote the recovery of pulmonary function and has few adverse reactions.